As­traZeneca gives up on late-stage IL-23 drug due to tri­al de­lays, com­pet­i­tive land­scape

As­traZeneca is shelv­ing an IL-23 an­ti­body that’s been through a wind­ing jour­ney around phar­ma — in­clud­ing stops at Am­gen and Al­ler­gan — and putting an end to Phase II and III tri­als test­ing the drug for in­flam­ma­to­ry bow­el dis­ease.

“The de­ci­sion to dis­con­tin­ue brazikum­ab’s IBD de­vel­op­ment fol­lows a re­cent re­view of brazikum­ab’s de­vel­op­ment time­line and the con­text of a com­pet­i­tive land­scape that has con­tin­ued to evolve,” a press re­lease reads.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.